Insider trade

Dexcom (DXCM): Director sold ~$688

Mark G Foletta, Director at Dexcom, sold ~$688 of Dexcom shares.

~$688
Approx. value · 8 sh @ $86.03
54K
Holds after · shares reported
Traded
Jul 15, 2025
Filed
Jul 17, 2025

What stands out in this filing

  • After this sale the filing reports 53,871 shares, held indirectly.
  • 8 shares at an average of $86.03 each, as reported on the form.
  • Filing box checked: sold under a Rule 10b5-1 plan.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. May 8, 2025CongressDisclosed purchase of DXCM — reported range $15,001 - $50,000
  2. May 12, 2025CongressDisclosed sale of DXCM — reported range $15,001 - $50,000
  3. May 15, 2025CongressDisclosed purchase of DXCM — reported range $1,001 - $15,000
  4. May 23, 2025InsiderOfficer sold ~$843K of DXCM shares in the open market
  5. May 27, 2025InsiderOfficer sold ~$526K of DXCM shares in the open market
  6. Jun 13, 2025InsiderDirector sold ~$214K of DXCM shares in the open market
  7. Jun 16, 2025Insider · 3 peopleInsiders: 3 sales (~$574K)
  8. Jun 26, 2025InsiderOfficer sold ~$125K of DXCM shares in the open market
  9. Jul 15, 2025 · this disclosureInsiderDirector sold ~$688 of DXCM shares in the open market

What came next

  1. Jul 15, 2025Insider · 2 peopleInsiders: 2 sales (~$277K)
  2. Jul 24, 2025FDARecall: Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 CGM Android App Model/Catalog Number: SW12299 Software Version: version 2.8.…
  3. Jul 24, 2025FDARecall: Brand Name: Dexcom ONE+ Continuous Glucose Monitoring System Product Name: Dexcom ONE+ Android CGM App Model/Catalog Number: SW14245 Software Version: versions…
  4. Jul 24, 2025FDARecall: Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 CGM watchOS App Model/Catalog Number: SW13355 Software Version: versions 2.8…
  5. Jul 24, 2025FDARecall: Brand Name: Dexcom ONE+ Continuous Glucose Monitoring System Product Name: Dexcom ONE+ iOS CGM App Model/Catalog Number: SW14244 Software Version: versions 1.4…
  6. Jul 24, 2025FDARecall: Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 CGM iOS App Model/Catalog Number: SW12300 Software Version: version 2.8.0 an…
  7. Jul 28, 2025InsiderOfficer sold ~$130K of DXCM shares in the open market
  8. Aug 15, 2025Insider · 2 peopleInsiders: 3 sales (~$263K)
  9. Aug 27, 2025Layoff notice · 6290-6350 Sequence Drive San Diego CA 92121Layoff notice filed in CA: 319 employees
  10. Aug 28, 2025FDARecall: Brand Name: Dexcom G6 Continuous Glucose Monitoring System Product Name: Dexcom G6 and G6 Pro Android US CGM App Model/Catalog Number: SW11678 Software Version…
  11. Sep 2, 2025InsiderOfficer sold ~$358K of DXCM shares in the open market
  12. Sep 4, 2025InsiderOfficer sold ~$117K of DXCM shares in the open market
  13. Sep 5, 2025InsiderDirector sold ~$54K of DXCM shares in the open market
  14. Sep 14, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“Effective September 14, 2025, Kevin R. Sayer, Chief Executive Officer (principal executive officer) and Chairman of the Board of DexCom, Inc. (“Dexcom” or the “Company”) is taking a temporary medical leave of absence.”
  15. Oct 24, 2025Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On October 24, 2025, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to ten directors and appointed Dr. Euan Ashley as a director, effective immediately.”
  16. Oct 27, 2025Court · District Court, S.D. New YorkSecurities lawsuit filed: Prime v. DexCom, Inc.
  17. Oct 30, 2025Company filing · Form 8-K · ResultsReported its results
  18. Oct 30, 20255% stakeThe Vanguard Group reported a passive stake (13G) of 12.6%
  19. Nov 10, 2025Court · District Court, S.D. New YorkSecurities lawsuit filed: Oakland County Employees Retirement System v. DexCom, Inc.
  20. Nov 10, 2025Insider · 2 peopleInsiders: 2 purchases (~$1.0M), 1 sale (~$218K)
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Dexcom

For Dexcom, OQRO holds 20 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DXCM page.

Other recent filings by Mark G Foletta, Director

The full history of Mark G Foletta, Director is on the profile page.

How this filing works

Explore the data

Common questions

Which Dexcom (DXCM) insider traded, and how much?

Mark G Foletta, Director at Dexcom, sold ~$688 of Dexcom shares. 8 shares at $86.03.

When did it happen, and when was it made public?

Traded: Jul 15, 2025. Filed: Jul 17, 2025. That is 2 days between the two dates.

What stands out in this filing?

After this sale the filing reports 53,871 shares, held indirectly. 8 shares at an average of $86.03 each, as reported on the form. Filing box checked: sold under a Rule 10b5-1 plan.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Dexcom recently?

For Dexcom, OQRO holds 20 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the DXCM page.

Does this mean DXCM stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Dexcom

Everything OQRO holds on this company is on its DXCM page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data